Climb Bio, Inc.

For the period ended Jun 30, 2025. Filed Aug 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 12, 2025

CLYM$10.29+16.0%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	June 30,	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$22,682	$87,229
Short-term marketable securities	62,021	63,690
Prepaid expenses and other current assets	2,681	3,953
Total current assets	87,384	154,872
Long-term marketable securities	102,702	61,610
Operating lease right-of-use assets	618	490
Property and equipment, net	314	199
Other long-term assets	1,368	16
Total assets	$192,386	$217,187
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$946	$705
Accrued expenses and other current liabilities	5,037	4,069
Operating lease liabilities	222	157
Total current liabilities	6,205	4,931
Operating lease liabilities, net of current portion	417	375
Total liabilities	6,622	5,306
Commitments and contingencies (Note 7)
Stockholders’ equity:
Common stock, $0.0001 par value; 250,000,000 shares authorized; 67,764,100 and 67,255,434 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively	7	7
Additional paid-in capital	444,762	441,727
Accumulated other comprehensive income	318	23
Accumulated deficit	(259,323)	(229,876)
Total stockholders’ equity	185,764	211,881
Total liabilities and stockholders’ equity	$192,386	$217,187

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.